Pricing Log in Create free account

Akari Therapeutics PLC (AKTX) vs NewcelX Ltd. (NCEL)

Akari Therapeutics PLC and NewcelX Ltd. are both Biotechnology companies. Akari Therapeutics PLC and NewcelX Ltd. are of similar size ($15.5M and $15.3M). Across the 10 metrics below, Akari Therapeutics PLC leads on 5 and NewcelX Ltd. on 5.

Valuation

Metric AKTX NCEL Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 0.79 4.61 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (316.31%) (61.20%) (33.15%)
Free cash flow yield (73.67%) (17.60%) (25.50%)

Profitability

Metric AKTX NCEL Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (140.09%) 0.00% (56.36%)
Return on assets (69.16%) 0.00% (48.04%)
Return on invested capital (167.93%) 0.00% 0.00%

Growth

Metric AKTX NCEL Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 68.99% 11.18% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKTX NCEL Biotechnology median
Debt to equity 0.04 0.06 0.00
Current ratio 0.60 0.40 4.72
Net debt to EBITDA 0.27 0.74 0.96

Dividend

Metric AKTX NCEL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AKTX NCEL Biotechnology median
Market cap 15.47m 15.34m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack